Howe & Rusling’s Acadia Pharmaceuticals ACAD Stock Holding History

Howe & Rusling’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-54	Closed	-$1K	–	323
2022 Q3	$1K	Sell	54 -50	-48%	-$810	﹤0.01%	933
2022 Q2	$1K	Buy	104 +45	+76%	+$840	﹤0.01%	920
2022 Q1	$1K	Hold	59	–	–	﹤0.01%	907
2021 Q4	$1K	Sell	59 -39	-40%	-$784	﹤0.01%	901
2021 Q3	$2K	Buy	98 +33	+51%	+$636	﹤0.01%	826
2021 Q2	$2K	Hold	65	–	–	﹤0.01%	777
2021 Q1	$2K	Sell	65 -4,665	-99%	-$205K	﹤0.01%	777
2020 Q4	$253K	Hold	4,730	–	–	0.04%	150
2020 Q3	$195K	Hold	4,730	–	–	0.03%	152
2020 Q2	$229K	Hold	4,730	–	–	0.04%	127
2020 Q1	$200K	Buy	4,730 +1,900	+67%	+$78.3K	0.04%	139
2019 Q4	$121K	Hold	2,830	–	–	0.02%	223
2019 Q3	$102K	Hold	2,830	–	–	0.02%	238
2019 Q2	$76K	Hold	2,830	–	–	0.01%	259
2019 Q1	$76K	Hold	2,830	–	–	0.01%	251
2018 Q4	$46K	Hold	2,830	–	–	0.01%	266
2018 Q3	$59K	Hold	2,830	–	–	0.01%	251
2018 Q2	$43K	Hold	2,830	–	–	0.01%	270
2018 Q1	$64K	Hold	2,830	–	–	0.01%	254
2017 Q4	$85K	Hold	2,830	–	–	0.02%	250
2017 Q3	$107K	Hold	2,830	–	–	0.02%	237
2017 Q2	$79K	Buy	+2,830	New	+$84.3K	0.02%	225

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Howe & Rusling's ACAD Position: Q4 2022 in Review

Howe & Rusling sold out of Acadia Pharmaceuticals (ACAD) in Q4 2022, closing a stake of 54 shares — an estimated $1K sold.

Howe & Rusling first reported a position in ACAD in Q2 2017 and held it in 22 quarters. The position peaked at $253K in Q4 2020. 227 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

Howe & Rusling reported no remaining Acadia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 54 Acadia Pharmaceuticals shares in Q4 2022, an estimated $1K.
Howe & Rusling first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 22 quarters.
Howe & Rusling's Acadia Pharmaceuticals position peaked at $253K in Q4 2020.
227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.